The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology.
The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology.
复制标题
DOI：
10.1161/atvbaha.117.310097
复制
发表时间：
2017-11
期刊：
影响因子：
--
通讯作者：
Owens GK
中科院分区：
文献类型：
--
作者：
Baylis RA;Gomez D;Mallat Z;Pasterkamp G;Owens GK
CANTOS试验的结果为支持人类动脉粥样硬化的炎症假说提供了令人兴奋的证据，并且是第一个显示靶向抗炎治疗临床益处的III期临床试验。然而，适度的整体临床效益和安全性问题，增加对致命感染的易感性，表明我们需要在这一关键领域做更多的工作。
The results of the CANTOS trial provide exciting evidence in support of the inflammatory hypothesis of atherosclerosis in humans, and is the first phase III clinical trial to show clinical benefit of a targeted anti-inflammatory therapy. However, the modest overall clinical benefit and safety concerns with increased susceptibility to fatal infections indicate that we need much more work in this critical area.